New data on AstraZeneca's promising prostate cancer therapy ZD4054 shows that patients taking the drug lived on average seven more months than patients receiving standard therapy. But the mid-stage trial failed to demonstrate an improvement in progression-free survival. The new data was unveiled at the European Cancer Conference in Barcelona and follows up on AstraZeneca's announcement last July that it would advance ZD4054 into a late-stage trial. Some analysts say that the therapy has the potential to become a blockbuster.
"The promising results from the EPOC study suggest that ZD4054 10mg once-daily has the potential to increase the median overall survival time for men with asymptomatic or mildly symptomatic metastatic HRPC," says the company, "with the benefit of a manageable side-effect profile and the convenience of once-daily oral dosing."
- here's the release on the study
ALSO: AstraZeneca is teaming with scientists at UT Southwestern Medical Center to study depression. Release
PLUS: AstraZeneca is now denying any intention of outsourcing all its manufacturing, saying the EVP who'd called production "not a core activity" was misquoted. Report
AstraZeneca inks $310M deal for asthma programs. Report
AstraZeneca looking at outsider CFO. Report
AstraZeneca cuts 7,600 jobs. Report
AstraZeneca to continue ambitious deal-making. Report